Rhopressa
(Netarsudil)ApprovedSmall molecule
Rhopressa is one of 44 small molecule programs targeting Glaucoma. It is currently in Approved.
3
Indications
10
Total Trials
1
Active Trials
43
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
182 competitors in Glaucoma
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Namenda
AbbViePhase 3
Eylea
RegeneronPhase 3
Rhopressa
FFalcon
Approved
Avastin
BBio-Thera Solutions
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Betoptic
SanofiPhase 3
Tocopherol
MM.D. Anderson Cancer Center
Phase 3
TFC-003
KKukje Pharma
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Corneal Edema2 trials
Intraocular Pressure1 trial
Adult1 trial
Glaucoma1 trial
Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma
Unknown status·—·Phase 4·NCT04981886·115 enrolled
2 more indications
Proliferative Vitreoretinopathy1 trial
Regulatory
FDA Approval Timeline[4]
Dec 18, 2017
RHOPRESSA
NDA NDA208254
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Netarsudil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]